Theranostic Drug Delivery Systems for Cancer Therapy

Theranostic drug delivery integrates therapeutic and diagnostic functions into a single platform, enabling targeted treatment of tumours while simultaneously monitoring drug distribution, activation and therapeutic response. Central to this approach are prodrugs or drug–imaging agent conjugates that remain inert during circulation and are activated by tumour‐associated stimuli such as pH gradients, redox potential, enzymes or reactive oxygen species. Carriers range from polymeric and lipid nanoparticles to self-assembled small-molecule frameworks and inorganic nanomaterials. These systems leverage surface ligands or passive accumulation to improve tumour specificity, minimise off-target toxicity and facilitate real-time imaging through modalities including fluorescence, magnetic resonance or photoacoustic signals. Recent advances emphasise stimuli-responsive designs—such as disulfide linkers cleaved by intracellular glutathione or photoactivatable groups released upon light exposure—to achieve spatiotemporal control over drug release. By combining precise dosing with non-invasive monitoring, theranostic platforms hold promise for personalised oncology, enabling rapid assessment of drug efficacy, informed dose adjustments and expedited clinical translation.

Research from Nature Portfolio

Recent studies have demonstrated the potential of light-activated prodrug conjugates to achieve precise tumour targeting and on-demand activation. One seminal system encapsulates a masked topoisomerase I inhibitor within a tumour-targeting scaffold bearing a photo-triggerable moiety and biotin ligand. Upon irradiation, the phototherapeutic agent releases the active inhibitor, interferes with DNA re-ligation, induces cancer cell apoptosis and allows temporal control of therapeutic action. In vivo investigations confirm robust tumour growth inhibition, underscoring the feasibility of phototheranostic approaches for spatiotemporally resolved cancer therapy.

Theranostic Drug Delivery Systems for Cancer Therapy publication trend

The graph below shows the total number of articles in theranostic drug delivery systems for cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Theranostic: A combined therapeutic and diagnostic approach within a single agent or platform.

Prodrug: A pharmacologically inactive compound that is converted into an active drug within the body in response to specific stimuli.

Activatable probe: A molecular construct that becomes detectable or releases its payload upon exposure to a target stimulus or environment.

Disulfide linker: A redox-sensitive chemical bond that can be cleaved by intracellular glutathione to release a drug.

Near-infrared (NIR) fluorescence: Optical emission in the 650–900 nm range used for deep-tissue imaging due to low background and high penetration.

Phototheranostic agent: A light-responsive compound that combines phototherapy and diagnostic imaging capabilities.

References

1. Cancer Cell‐Specific Fluorescent Prodrug Delivery Platforms. Advanced Science (2023).
2. Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor. Scientific Reports (2016).
3. Pro-organic radical contrast agents (“pro-ORCAs”) for real-time MRI of pro-drug activation in biological systems. Polymer Chemistry (2020).
4. Redox Dual-Responsive and O2‑Evolving Theranostic Nanosystem for Highly Selective Chemotherapy against Hypoxic Tumors. Theranostics (2019).